EXELAN PHARMACEUTICALS, INC.

Exelan Pharmaceuticals Inc. specializes in the manufacturing and supply of specialty pharmaceutical preparations, with deep expertise in oral solid dosage forms such as capsules and tablets for complex therapeutic agents. The company focuses on high-demand biologics and branded generics, particularly in oncology and bone health, delivering FDA-regulated, GMP-compliant products under strict quality control protocols. Their technical capabilities include formulation development, active pharmaceutical ingredient (API) integration, and end-to-end production of oral medications meeting USP and cGMP standards, with demonstrated proficiency in handling sensitive therapeutics like lenalidomide and alendronate sodium. The contractor maintains a strong, recurring relationship with the Department of Veterans Affairs, supplying critical medications to VA medical centers across the nation. Additional contracts are awarded through Department of Defense network contract offices and DLA Troop Support, indicating consistent provision of pharmaceuticals to military and veteran healthcare systems. These engagements reflect a trusted role in sustaining the federal supply chain for specialty drugs used in chronic and complex care settings. Exelan’s primary industry focus is NAICS 325412—Pharmaceutical Preparation Manufacturing—where they operate as a niche supplier of oral pharmaceuticals for government health programs. Their vertical specialization lies in oncology and immunomodulatory agents, positioning them as a reliable source for high-complexity, low-volume medications that require stringent manufacturing controls. They also possess limited experience in medicinal and botanical manufacturing under NAICS 325411, expanding their portfolio into plant-derived therapeutics. As a small business entity structured as a 2L (small business, non-small disadvantaged), Exelan operates from Boca Raton, Florida, with no federal certifications on record. Their market positioning is defined by precision manufacturing for federal healthcare demand, serving as a critical link in the government’s pharmaceutical logistics network without reliance on certification-based procurement advantages.